These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 2500756)

  • 21. Pharmacokinetics of total and free valproic acid during monotherapy in infants.
    Herngren L; Lundberg B; Nergårdh A
    J Neurol; 1991 Sep; 238(6):315-9. PubMed ID: 1940980
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemical and immunochemical comparison of protein adduct formation of four carboxylate drugs in rat liver and plasma.
    Bailey MJ; Dickinson RG
    Chem Res Toxicol; 1996; 9(3):659-66. PubMed ID: 8728513
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Disposition of fentanyl in human blood].
    Lehmann KA; Schmitz KF; Daub D
    Anaesthesist; 1983 Jul; 32(7):329-34. PubMed ID: 6614420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hyperammonaemia and hepatotoxicity during chronic valproate therapy: enhancement by combination with other antiepileptic drugs.
    Ratnaike RN; Schapel GJ; Purdie G; Rischbieth RH; Hoffmann S
    Br J Clin Pharmacol; 1986 Jul; 22(1):100-3. PubMed ID: 3091053
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Valproate protein binding following rapid intravenous administration of high doses of valproic acid in patients with epilepsy.
    Dutta S; Faught E; Limdi NA
    J Clin Pharm Ther; 2007 Aug; 32(4):365-71. PubMed ID: 17635338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Propranolol binding with plasma proteins and erythrocytes].
    Gneushev ET; Mamedov TSh; Gneusheva IA; Sivkov II
    Farmakol Toksikol; 1991; 54(1):55-7. PubMed ID: 1860502
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of free and total sodium valproate in adolescents and young adults during maintenance therapy.
    Herngren L; Nergårdh A
    J Neurol; 1988 Nov; 235(8):491-5. PubMed ID: 3145327
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distribution of sodium valproate in normal whole blood and in blood from patients with renal or hepatic disease.
    Shirkey RJ; Jellett LB; Kappatos DC; Maling TJ; Macdonald A
    Eur J Clin Pharmacol; 1985; 28(4):447-52. PubMed ID: 3928388
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dose-dependent inhibition in plasma protein binding of valproic acid during continued treatment in guinea-pigs.
    Yu HY; Shen YZ
    J Pharm Pharmacol; 1992 May; 44(5):408-12. PubMed ID: 1359055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Binding and distribution of chlordiazepoxide (Radepur) and its metabolites in the erythrocyte-plasma and erythrocyte-buffer systems].
    Terhaag B
    Acta Biol Med Ger; 1976; 35(10):1373-8. PubMed ID: 1020569
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determination of unbound valproic acid in plasma using centrifugal ultrafiltration and gas chromatography:Application in TDM.
    Gu X; Yu S; Peng Q; Ma M; Hu Y; Zhou B
    Anal Biochem; 2020 Jan; 588():113475. PubMed ID: 31634440
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nonlinear binding of valproic acid (VPA) and E-delta 2-valproic acid to rat plasma proteins.
    Semmes RL; Shen DD
    Pharm Res; 1990 May; 7(5):461-7. PubMed ID: 2114617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determination of unbound valproic acid concentration in plasma by equilibrium dialysis and gas--liquid chromatography: methodological aspects and observations in epileptic patients.
    Riva R; Albani F; Baruzzi A; Galvani I; Perucca E
    Ther Drug Monit; 1982; 4(4):341-52. PubMed ID: 6818733
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rapid fluorometric analysis of unbound salicylate in whole blood.
    Baselt RC; Stewart CB
    Res Commun Chem Pathol Pharmacol; 1976 Oct; 15(2):351-60. PubMed ID: 981790
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Unbound valproate fraction in plasma and subcutaneous microdialysate in steady state and after a single dose in humans.
    Lindberger M; Tomson T; Ståhle L
    Ther Drug Monit; 2003 Jun; 25(3):378-83. PubMed ID: 12766568
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Binding parameters of valproic acid to serum protein in healthy adults at steady state.
    Kodama Y; Koike Y; Kimoto H; Yasunaga F; Takeyama M; Teraoka I; Fujii I
    Ther Drug Monit; 1992 Feb; 14(1):55-60. PubMed ID: 1546390
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma protein-binding and CSF concentrations of valproic acid in man following acute oral dosing.
    Rapeport WG; Mendelow AD; French G; MacPherson P; Teasdale E; Agnew E; Thompson GG; Brodie MJ
    Br J Clin Pharmacol; 1983 Oct; 16(4):365-9. PubMed ID: 6414500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intra-dose variation in plasma protein binding of sodium valproate in epileptic patients.
    Marty JJ; Kilpatrick CJ; Moulds RF
    Br J Clin Pharmacol; 1982 Sep; 14(3):399-404. PubMed ID: 6812608
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of valproic acid in volunteers after a single dose study.
    Bialer M; Hussein Z; Raz I; Abramsky O; Herishanu Y; Pachys F
    Biopharm Drug Dispos; 1985; 6(1):33-42. PubMed ID: 3921078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonlinear elimination and hepatic concentration of conjugation-metabolite of valproate in guinea-pigs.
    Yu HY; Wu MS; Shen YZ
    Biopharm Drug Dispos; 1993 May; 14(4):297-312. PubMed ID: 8499581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.